Abbott Laboratories (XSWX:ABT) Total Liabilities : CHF29,738 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Abbott Laboratories Total Liabilities?

Abbott Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 was CHF29,738 Mil.

Abbott Laboratories's quarterly Total Liabilities declined from Jun. 2023 (CHF32,369.38 Mil) to Sep. 2023 (CHF30,942.64 Mil) and declined from Sep. 2023 (CHF30,942.64 Mil) to Dec. 2023 (CHF29,737.88 Mil).

Abbott Laboratories's annual Total Liabilities declined from Dec. 2021 (CHF36,077.41 Mil) to Dec. 2022 (CHF34,965.74 Mil) and declined from Dec. 2022 (CHF34,965.74 Mil) to Dec. 2023 (CHF29,737.88 Mil).

Abbott Laboratories Total Liabilities Historical Data

The historical data trend for Abbott Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Total Liabilities Chart

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

35,949.40

35,131.78

36,077.41

34,965.74

29,737.88

Abbott Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															33,838.13	32,369.38	30,942.64	29,737.88	-

Abbott Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Abbott Laboratories's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11969.697	+	(12581.11	+	2997.398
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	491.206	+	1698.467)
	=	29,738

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	63315.467	-	33577.59
	=	29,738

Abbott Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11969.697	+	(12581.11	+	2997.398
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	491.206	+	1698.467)
	=	29,738

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	63315.467	-	33577.59
	=	29,738

Abbott Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories (XSWX:ABT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (XSWX:ABT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ABT:USA ABT:Mexico 0Q15:UK ABL:Germany ABT:Chile ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.